Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors

Main Inclusion Criteria: * Written informed consent * Progressive locally advanced or metastatic malignancy * Prior administration of standard treatment for primary and relapsed malignancy * Eastern Cooperative Oncology Group Performance Status ≤1 * Patients with central venous access device in place (central venous catheter or porta-cath) * Age ≥18 and ≤70 years * Identification of defective DNA repair via HR * Adequate bone marrow, renal, and hepatic function * Hemoglobin ≥10 g/dl * Neutrophil count ≥1,500/mm3 * Platelet count ≥100,000/µl * Bilirubin ≤1.5 x upper limit of normal (ULN) * ALT and AST ≤2.5 x ULN (≤5 x ULN in patients with hepatic tumor involvement) * Alkaline phosphatase ≤2.5 x ULN * PT-INR/PTT ≤1.5 x ULN * Albumin ≥25 g/l * Creatine kinase ≤2.5 x ULN * Serum creatinine 1.5 mg/dl or creatinine clearance 51 ml/min Main Exclusion Criteria: * Hematological malignancies and primary brain tumors. * Concurrent treatment in another interventional clinical trial * Prior treatment with PARP Inhibitors * Patients with platinum-refractory disease, defined as progressive disease during or immediately after treatment with platinum based chemotherapy * Persistent toxicity (\> Grade 2 according to CTCAE 5.0) * Dementia or significant impairment of cognitive state * History of HIV infection * Clinical signs of active infection (\>Grade 2 according to CTCAE 4.03) * History of viral hepatitis (HBV or HCV) * Epilepsy requiring pharmacologic treatment * Pregnancy * Major surgical intervention 4 weeks prior to study inclusion * Known hypersensitivity to any of the study drugs * Hematologic malignancy * QTc time prolongation \>500 ms or history of familial long-QT-syndrome * Heart failure NYHA III/IV * Severe obstructive or restrictive ventilation disorder * Concomitant use of known strong CYP3A Inhibitors * Concomitant use of known strong CYP3A inducers